LY 178002 is an effective inhibitor of 5-lipoxygenase (5-LPO), phospholipase A2 (IC50: 0.6 μM for 5-lipoxygenase). LY 178002 also inhibits cellular production of LTB4 by human polymorphonuclear leukocytes and displays relatively weak inhibition on cyclooxygenase.

LY178002 suppresses the generation of LTB4, PLA2 and FCO (IC50s of 0.1, 6.3 and 4.2 μM) .

LY 178002 (50 mg/kg) inhibits soft tissue swelling in the uninjected paw by 81% and inhibits bone damage in rats. LY178002 (50 mg/kg; p.o.) inhibits the uninjected paw swelling by 75%, in the established FCA model. The minimum effective dose for LY178002 is 10 mg/kg p.o.

107889-32-7

C18H25NO2S

319.46

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years